Clinical Trial

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated August 26, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-12-31; most recent amendment 2024-08-22.
Trial Details
NCT Number NCT05176665
Lead Sponsor Shanghai EpimAb Biotherapeutics Co., Ltd.
Collaborators: Labcorp Corporation of America Holdings, Inc
Conditions Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor
Enrollment 152 participants
Start Date 2021-10-21
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-26